Results 211 to 220 of about 5,278,927 (357)

Business Barriers Slowing the Pace of Cancer Immunotherapy Research and Development [PDF]

, 2007
Rabiya S. Tuma
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Cancer Research Funding in Africa. [PDF]

Commun Med (Lond)
Afolaranmi O, Garton EM, Dada OE, Virani SS, Shour AR, Onitilo AA, Zafar SN.   +6 more
europepmc   +1 more source

Digital pathology imaging artificial intelligence in cancer research and clinical trials: An NCI workshop report

Hala R. Makhlouf, Miguel R. Ossandon, Keyvan Farahani, Irina Lubensky, Lyndsay N. Harris   +4 more
openalex   +1 more source

Translational Research in Colorectal Cancer [PDF]

, 2018
Karin M. Hardiman
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

CCDC137: A key hub for RNA and epigenetic regulation in cancer research (Review). [PDF]

Int J Oncol
Zhao X, Zhang W, Yu X, Zhao X, Dai X, Chen S, Wang Y, Cheng J, Zheng W.   +8 more
europepmc   +1 more source

Supplementary Table from Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda

Elisabeth F. Beaber, Aruna Kamineni, Andrea N. Burnett-Hartman, Brian Hixon, Sarah C. Kobrin, Christopher I. Li, Malia Oliver, Katharine A Rendle, Celette Sugg Skinner, Kaitlin Todd, Yingye Zheng, Rebecca A. Ziebell, Erica S. Breslau, Jessica Chubak, Douglas A. Corley, Robert T Greenlee, Jennifer S Haas, Ethan A. Halm, Stacey Honda, Christine Neslund-Dudas, Debra P. Ritzwoller, Joanne E. Schottinger, Jasmin A. Tiro, Anil Vachani, V Paul Doria-Rose   +24 more
openalex   +1 more source

INNV-33. IMPLEMENTATION OF ELECTRONIC DATA CAPTURE FOR USE IN NATURAL HISTORY STUDIES: UTILITY OF CENTER FOR CANCER RESEARCHS (CCR) LABMATRIX AND SCRIBE SYSTEMS FOR THE NEURO-ONCOLOGY BRANCH NATURAL HISTORY STUDY (NOB-NHS) [PDF]

, 2018
Elizabeth Vera, Jason Levine, Ming Ji, Ewa Grajkowska, Sonja Crandon, Mark R. Gilbert, Terri S. Armstrong   +6 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source